FDA Approval: Encorafenib + Binimetinib in BRAF V600E NSCLC
Podcast | English | 42 Min
Image For Activity Cover
Cost
$0.00
Credit
No Credit Offered

On October 11, 2023, the U.S. FDA granted approval to Encorafenib and Binimetinib for advanced NSCLC harboring a BRAF V600E mutation based on the phase II PHAROS trial. In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the Encorafenib and Binimetinib regimens, as well as the underlying biology for these therapies, with three internationally known clinicians and researchers.

 
Podcast Host:
  • Stephen Liu, MD, Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center, USA 

Podcast Guests: 

  • Sandra Ortiz-Cuaran, MD, Lung Cancer Translational Scientist, Centre Léon Bérard / Cancer Research Center of Lyon,France
  • Greg Riely, MD, PhD, Vice Chair of Clinical Research, Memorial Sloan Kettering Cancer Center, USA
  • Estelamari Rodriquez, MD, Associate Director of Community Outreach, The University of Miami, USA
Powered By